Home > Press Releases > Therapeutics & Biotech Niche Areas Market

Therapeutics & Biotech Niche Areas Market Likely to Surpass USD 559 Billion by 2035

Report Code: HC-88440  |  Published in: Oct 2025, By MarketGenics  |  Number of pages: 332
Get PDF
Buy

Exploring novel growth opportunities on, “Therapeutics & Biotech Niche Areas Market Size, Share & Trends Analysis Report by Therapeutic Area (Oncology, Rare Diseases, Immunology & Inflammation, Neurology, Infectious Diseases, Cardiovascular Diseases, Respiratory Diseases), Technology Platform, Molecule Type, Route of Administration, Development Stage, End-users,and Geography (North America, Europe, Asia Pacific, Middle East, Africa, and South America) – Global Industry Data, Trends, and Forecasts, 2025–2035” An In‑depth study examining emerging pathways in the therapeutics & biotech niche areas market identifies critical enablers from localized R&D and supply-chain agility to digital integration and regulatory convergence positioning therapeutics & biotech niche areas for sustained international growth

Global Therapeutics & Biotech Niche Areas Market Forecast 2035:

According to the report, the global therapeutics & biotech niche areas market is likely to grow from USD 173.6 Billion in 2025 to USD 558.7 Billion in 2035 at a highest CAGR of 12.4% during the time period. The therapeutics & biotech niche areas market is growing rapidly, as a result of the inclusion of AI-driven drug design, high-throughputs molecular screening, lipid-nanoparticle delivery technologies and collaborative cloud-based platforms. The integration of these technologies facilitates R&D, enhances precision for therapeutic development, and accelerates clinical dissemination in oncology, rare diseases and next-generation biologics.

The RNA therapeutics paradigm is being supported by modular platform technologies, automated RNA syntheses and predictive modelling, to design candidates faster and produce them in large quantities and tailored therapies to oncology, rare genetic diseases, and infectious diseases. An example is that in June 2025, Eli Lilly announced that it was acquiring Verve Therapeutics, a gene-editing company, at a valuation of $1.3 billion so that it can strengthen its pipeline of investigative drugs. Verve is preparing a CRISPR gene therapy to attack the PCSK9 gene that causes high cholesterol and cardiovascular disease. The acquisition highlights the growing focus on gene-editing technology and its capacity to change the paradigms of treatment.

Pharmaceuticals teamed with U.S.-based Nabla Bio to foster drug discovery based upon Nabla's AI platform, JAM, this platform enables the design of novel protein-based therapeutics for complex disease in just three to four weeks from design to the lab. This type of partnership enables more efficient drug discovery, reduces development and adaptation timeframes to interact more efficiently with patients, and establishes a development and commercialization ecosystem founded on advanced technologies. In general, the application of these sophisticated technologies will enable more accelerated, more precise, and effective therapeutic innovation within the biotechnology industry.

“Key Driver, Restraint, and Growth Opportunity Shaping the Global Therapeutics & Biotech Niche Areas Market”

The therapeutics and biotech niche areas market is rapidly developing because of the innovations in oncology, rare genetic disorders, immunotherapy and gene therapy. Technologies on modular platforms have led to innovations in automated high-throughput screening, AI-assisted target identification, and predictive modeling that enable faster design of candidates, optimize the therapeutic delivery, and enhance the clinical success rate of more innovative therapeutic candidates. The small-midsized biotech firms, the listed pharmaceutical firms, and the research organizations also contribute to the improvement of research and development and the scale supply of these innovative therapeutics throughout the world.

High costs of development, regulatory demands, unscalable manufacture and logistical complexities of biologics and gene therapies delivery are some of the numerous challenges that have led to delays or failure to complete a clinical trial or commercialize products. The intellectual property, nonhomogenous global regulatory environment and necessary specific infrastructure may also create or hinder the clinical trials and resulting commercialization and delivery to patients, especially in developing parts of the world.

Government funding, industry-government interactions, and strategic partnerships between biotech start-ups and existing pharmaceutical companies will reduce the cost, improve accessibility, and accelerate the innovation. Such initiatives are likely to produce a wider utilization, better patient results, and a long-term development in the market of world therapeutic and biotech niche fields.

Through government financing, public-corporate collaboration, and strategic alliance between the biotech startups and developed pharmaceutical firms, the costs, access, and innovation will be reduced, extended, and expedited. These programs are expected to create a broader usage, better patient results, and a sustainable growth of the global therapeutics and biotech niche areas market.

Expansion and Regional Growth of Cell and Gene Therapy Driving the Global Therapeutics & Biotech Niche Areas Market

  • Among the most rapidly expanding fields is cell and gene therapy where companies are making new biologics, gene-editing tools and RNA-based therapeutics to meet unmet medical needs in oncology, rare genetic diseases and immunologic diseases. New companies which specialize in therapeutics, biotech niche sectors will allow developers to streamline these therapies in the realms of safety, efficacy and targeted delivery. As an example, in 2023 Regeneron Pharmaceuticals extended its collaboration with Intellia Therapeutics to co-develop CRISPR-based, in vivo gene-editing therapies to treat rare genetic diseases. This partnership will use the AI-directed gene-editing platform developed by Intellia to eliminate the time and resources spent on finding the candidate and enhancing delivery to shorten preclinical cycles and boost the probability of clinical success. The above developments underscore the growing relevance of new horizontal therapeutic platforms to create accurate, effective, and scalable therapies across different disease conditions across the world.
  • The rising investments in the health sector, the growing number of incurable and rare diseases, and increased access to up-to-date treatment contribute to the tremendous development of emerging areas. Due to the rapid implementation of gene and cell therapies in China, India and Brazil, new opportunities in global expansion are becoming possible. This regional development alongside the current trend in technological advancements may be part of the therapeutics and biotech niche areas long-term adoption and development on a global level.

Regional Analysis of Global Therapeutics & Biotech Niche Areas Market

  • North America remains the leader in the global therapeutics & biotech niche areas market, owing to its advanced biomanufacturing ecosystem, robust R&D ecosystem, and high levels of government support for innovation. The region takes full advantage of AI-assisted drug discovery, modular biofoundries, high-throughput screening, and precision gene-editing platforms to accelerate the development of therapeutics and optimize biologics, cell, and gene therapies. The combination of various U.S. and Canadian government funding programs, public-private partnerships, and biotech accelerators serves as a powerful enabler, to spur R&D, commercialization and scaling up advanced therapeutics. All of these create a strong, differentiated position for North America to continue to lead in innovation in the market and continue to expand in therapeutics and biotech.
  • The Asia Pacific region is accelerating growth in the global therapeutics & biotech niche areas market at the fastest rate, driven by an increase in healthcare expenditures, a growing rate of chronic and rare diseases, and expanded access to innovative therapeutic technologies. The rapid adoption of gene and cell therapies, AI-enabled drug discovery platforms, and cloud-based R&D activities in local markets such as China, India, and Japan are facilitating innovation and new treatment development in the region. Further, favorable government policies, expanding health care infrastructure, and private/public partnerships are stimulating market entry and acceptance.

Prominent players operating in the global therapeutics & biotech niche areas market are 10x Genomics, Inc., AbbVie Inc., Alexion Pharmaceuticals (AstraZeneca), Alnylam Pharmaceuticals, Inc., Amgen Inc., Biogen Inc., BioMarin Pharmaceutical Inc., BioNTech SE, bluebird bio, Inc., Bristol-Myers Squibb Company, CRISPR Therapeutics AG, Editas Medicine, Inc., Genentech (Roche Group), Gilead Sciences, Inc., Illumina, Inc., Intellia Therapeutics, Inc., Ionis Pharmaceuticals, Inc., Moderna, Inc., Novartis AG, Regeneron Pharmaceuticals, Inc., Roche Holding AG, Sarepta Therapeutics, Inc., Vertex Pharmaceuticals Incorporated, Other Key Players.

The global Therapeutics & Biotech Niche Areas market has been segmented as follows:

Global Therapeutics & Biotech Niche Areas Market Analysis, By Therapeutic Area

  • Oncology
    • Solid Tumors
    • Hematological Malignancies
    • Immunotherapy
    • Others
  • Rare Diseases
    • Genetic Disorders
    • Metabolic Disorders
    • Orphan Diseases
    • Others
  • Immunology & Inflammation
    • Autoimmune Diseases
    • Inflammatory Disorders
    • Others
  • Neurology
    • Neurodegenerative Diseases
    • Neuropsychiatric Disorders
    • Others
  • Infectious Diseases
    • Viral Infections
    • Bacterial Infections
    • Fungal Infections
    • Others
  • Cardiovascular Diseases
    • Metabolic Disorders
    • Diabetes
    • Obesity
    • Others
  • Respiratory Diseases

Global Therapeutics & Biotech Niche Areas Market Analysis, by Technology Platform

  • Gene Therapy
    • In Vivo Gene Therapy
    • Ex Vivo Gene Therapy
  • Cell Therapy
    • CAR-T Cell Therapy
    • Stem Cell Therapy
    • NK Cell Therapy
    • Others
  • RNA Therapeutics
    • mRNA Therapy
    • siRNA Therapy
    • Antisense Oligonucleotides
    • Others
  • Antibody Engineering
    • Monoclonal Antibodies
    • Bispecific Antibodies
    • Antibody-Drug Conjugates (ADCs)
    • Others
  • CRISPR & Gene Editing
  • Protein Engineering
  • Microbiome Therapeutics
  • Oncolytic Virus Therapy

Global Therapeutics & Biotech Niche Areas Market Analysis, by Molecule Type

  • Biologics
    • Monoclonal Antibodies
    • Recombinant Proteins
    • Vaccines
    • Biosimilars
    • Others
  • Small Molecules
    • Kinase Inhibitors
    • Enzyme Inhibitors
    • Targeted Small Molecules
    • Others
  • Nucleic Acid-Based Therapeutics
    • DNA-Based
    • RNA-Based
  • Cell-Based Products
  • Tissue Engineering Products

Global Therapeutics & Biotech Niche Areas Market Analysis, by Route of Administration

  • Injectable
    • Intravenous
    • Subcutaneous
    • Intramuscular
    • Intrathecal
    • Others
  • Oral
  • Topical
  • Inhalation
  • Transdermal
  • Implantable

Global Therapeutics & Biotech Niche Areas Market Analysis, by Development Stage

  • Preclinical
  • Clinical Trials
  • Approved/Marketed
  • Post-Marketing Surveillance

Global Therapeutics & Biotech Niche Areas Market Analysis, by End-users

  • Healthcare Providers
    • Diagnosis & Treatment
    • Patient Monitoring
    • Precision Medicine
    • Others
  • Research & Academic Institutions
    • Drug Discovery
    • Translational Research
    • Basic Research
    • Others
  • Pharmaceutical & Biotech Companies
    • Product Development
    • Manufacturing
    • Commercialization
    • Others
  • Contract Research Organizations (CROs)
    • Clinical Trials
    • Regulatory Support
    • Others
  • Contract Manufacturing Organizations (CMOs)
    • Commercial Production
    • Process Development
  • Diagnostic Laboratories
  • Government & Regulatory Bodies
  • Other End-users

Global Therapeutics & Biotech Niche Areas Market Analysis, by Region

  • North America
  • Europe
  • Asia Pacific
  • Middle East
  • Africa
  • South America

About Us

MarketGenics is a global market research and management consulting company empowering decision makers from startups, Fortune 500 companies, non-profit organizations, universities and government institutions. Our main goal is to assist and partner organizations to make lasting strategic improvements and realize growth targets. Our industry research reports are designed to provide granular quantitative information, combined with key industry insights, aimed at assisting sustainable organizational development.

We serve clients on every aspect of strategy, including product development, application modeling, exploring new markets and tapping into niche growth opportunities.

Contact Us

USA Address:

800 N King Street Suite 304 #4208 Wilmington, DE 19801 United States.

+1(302)303-2617

info@marketgenics.co

India Address:

3rd floor, Indeco Equinox, Baner Road, Baner, Pune, Maharashtra 411045 India.

sales@marketgenics.co

Table of Contents

  • 1. Research Methodology and Assumptions
    • 1.1. Definitions
    • 1.2. Research Design and Approach
    • 1.3. Data Collection Methods
    • 1.4. Base Estimates and Calculations
    • 1.5. Forecasting Models
      • 1.5.1. Key Forecast Factors & Impact Analysis
    • 1.6. Secondary Research
      • 1.6.1. Open Sources
      • 1.6.2. Paid Databases
      • 1.6.3. Associations
    • 1.7. Primary Research
      • 1.7.1. Primary Sources
      • 1.7.2. Primary Interviews with Stakeholders across Ecosystem
  • 2. Executive Summary
    • 2.1. Global Therapeutics & Biotech Niche Areas Market Outlook
      • 2.1.1. Therapeutics & Biotech Niche Areas Market Size (Value - US$ Bn), and Forecasts, 2021-2035
      • 2.1.2. Compounded Annual Growth Rate Analysis
      • 2.1.3. Growth Opportunity Analysis
      • 2.1.4. Segmental Share Analysis
      • 2.1.5. Geographical Share Analysis
    • 2.2. Market Analysis and Facts
    • 2.3. Supply-Demand Analysis
    • 2.4. Competitive Benchmarking
    • 2.5. Go-to- Market Strategy
      • 2.5.1. Customer/ End-use Industry Assessment
      • 2.5.2. Growth Opportunity Data, 2025-2035
        • 2.5.2.1. Regional Data
        • 2.5.2.2. Country Data
        • 2.5.2.3. Segmental Data
      • 2.5.3. Identification of Potential Market Spaces
      • 2.5.4. GAP Analysis
      • 2.5.5. Potential Attractive Price Points
      • 2.5.6. Prevailing Market Risks & Challenges
      • 2.5.7. Preferred Sales & Marketing Strategies
      • 2.5.8. Key Recommendations and Analysis
      • 2.5.9. A Way Forward
  • 3. Industry Data and Premium Insights
    • 3.1. Global Healthcare Industry Overview, 2025
      • 3.1.1. Healthcare Industry Ecosystem Analysis
      • 3.1.2. Key Trends for Healthcare Industry
      • 3.1.3. Regional Distribution for Healthcare Industry
    • 3.2. Supplier Customer Data
    • 3.3. Technology Roadmap and Developments
    • 3.4. Trade Analysis
      • 3.4.1. Import & Export Analysis, 2025
      • 3.4.2. Top Importing Countries
      • 3.4.3. Top Exporting Countries
    • 3.5. Trump Tariff Impact Analysis
      • 3.5.1. Manufacturer
        • 3.5.1.1. Based on the component & Raw material
      • 3.5.2. Supply Chain
      • 3.5.3. End Consumer
    • 3.6. Raw Material Analysis
  • 4. Market Overview
    • 4.1. Market Dynamics
      • 4.1.1. Drivers
        • 4.1.1.1. Increasing adoption of genomic profiling, AI-based biomarker discovery, and targeted therapeutic platforms.
        • 4.1.1.2. Growing unmet clinical needs driving R&D investment and regulatory incentives (e.g., orphan drug designations).
        • 4.1.1.3. Rapid progress in gene and cell therapies, mRNA therapeutics, and next-generation biologics enhancing treatment efficacy and pipeline diversity.
      • 4.1.2. Restraints
        • 4.1.2.1. Complex production processes, stringent quality control, and limited CDMO capacity constrain scalability and profitability.
        • 4.1.2.2. Evolving global regulatory frameworks and limited payer readiness for high-cost, one-time therapies slow market adoption.
    • 4.2. Key Trend Analysis
    • 4.3. Regulatory Framework
      • 4.3.1. Key Regulations, Norms, and Subsidies, by Key Countries
      • 4.3.2. Tariffs and Standards
      • 4.3.3. Impact Analysis of Regulations on the Market
    • 4.4. Value Chain Analysis
      • 4.4.1. Preclinical development
      • 4.4.2. Clinical development
      • 4.4.3. Regulatory & approval
      • 4.4.4. Market access, pricing & reimbursement
    • 4.5. Cost Structure Analysis
      • 4.5.1. Parameter’s Share for Cost Associated
      • 4.5.2. COGP vs COGS
      • 4.5.3. Profit Margin Analysis
    • 4.6. Pricing Analysis
      • 4.6.1. Regional Pricing Analysis
      • 4.6.2. Segmental Pricing Trends
      • 4.6.3. Factors Influencing Pricing
    • 4.7. Porter’s Five Forces Analysis
    • 4.8. PESTEL Analysis
    • 4.9. Global Therapeutics & Biotech Niche Areas Market Demand
      • 4.9.1. Historical Market Size – Value (US$ Bn), 2020-2024
      • 4.9.2. Current and Future Market Size - Value (US$ Bn), 2025–2035
        • 4.9.2.1. Y-o-Y Growth Trends
        • 4.9.2.2. Absolute $ Opportunity Assessment
  • 5. Competition Landscape
    • 5.1. Competition structure
      • 5.1.1. Fragmented v/s consolidated
    • 5.2. Company Share Analysis, 2025
      • 5.2.1. Global Company Market Share
      • 5.2.2. By Region
        • 5.2.2.1. North America
        • 5.2.2.2. Europe
        • 5.2.2.3. Asia Pacific
        • 5.2.2.4. Middle East
        • 5.2.2.5. Africa
        • 5.2.2.6. South America
    • 5.3. Product Comparison Matrix
      • 5.3.1. Specifications
      • 5.3.2. Market Positioning
      • 5.3.3. Pricing
  • 6. Global Therapeutics & Biotech Niche Areas Market Analysis, by Therapeutic Area
    • 6.1. Key Segment Analysis
    • 6.2. Therapeutics & Biotech Niche Areas Market Size (Value - US$ Bn), Analysis, and Forecasts, by Therapeutic Area, 2021-2035
      • 6.2.1. Oncology
        • 6.2.1.1. Solid Tumors
        • 6.2.1.2. Hematological Malignancies
        • 6.2.1.3. Immunotherapy
        • 6.2.1.4. Others
      • 6.2.2. Rare Diseases
        • 6.2.2.1. Genetic Disorders
        • 6.2.2.2. Metabolic Disorders
        • 6.2.2.3. Orphan Diseases
        • 6.2.2.4. Others
      • 6.2.3. Immunology & Inflammation
        • 6.2.3.1. Autoimmune Diseases
        • 6.2.3.2. Inflammatory Disorders
        • 6.2.3.3. Others
      • 6.2.4. Neurology
        • 6.2.4.1. Neurodegenerative Diseases
        • 6.2.4.2. Neuropsychiatric Disorders
        • 6.2.4.3. Others
      • 6.2.5. Infectious Diseases
        • 6.2.5.1. Viral Infections
        • 6.2.5.2. Bacterial Infections
        • 6.2.5.3. Fungal Infections
        • 6.2.5.4. Others
      • 6.2.6. Cardiovascular Diseases
        • 6.2.6.1. Metabolic Disorders
        • 6.2.6.2. Diabetes
        • 6.2.6.3. Obesity
        • 6.2.6.4. Others
      • 6.2.7. Respiratory Diseases
  • 7. Global Therapeutics & Biotech Niche Areas Market Analysis, by Technology Platform
    • 7.1. Key Segment Analysis
    • 7.2. Therapeutics & Biotech Niche Areas Market Size (Value - US$ Bn), Analysis, and Forecasts, by Technology Platform, 2021-2035
      • 7.2.1. Gene Therapy
        • 7.2.1.1. In Vivo Gene Therapy
        • 7.2.1.2. Ex Vivo Gene Therapy
      • 7.2.2. Cell Therapy
        • 7.2.2.1. CAR-T Cell Therapy
        • 7.2.2.2. Stem Cell Therapy
        • 7.2.2.3. NK Cell Therapy
        • 7.2.2.4. Others
      • 7.2.3. RNA Therapeutics
        • 7.2.3.1. mRNA Therapy
        • 7.2.3.2. siRNA Therapy
        • 7.2.3.3. Antisense Oligonucleotides
        • 7.2.3.4. Others
      • 7.2.4. Antibody Engineering
        • 7.2.4.1. Monoclonal Antibodies
        • 7.2.4.2. Bispecific Antibodies
        • 7.2.4.3. Antibody-Drug Conjugates (ADCs)
        • 7.2.4.4. Others
      • 7.2.5. CRISPR & Gene Editing
      • 7.2.6. Protein Engineering
      • 7.2.7. Microbiome Therapeutics
      • 7.2.8. Oncolytic Virus Therapy
  • 8. Global Therapeutics & Biotech Niche Areas Market Analysis, by Molecule Type
    • 8.1. Key Segment Analysis
    • 8.2. Therapeutics & Biotech Niche Areas Market Size (Value - US$ Bn), Analysis, and Forecasts, by Molecule Type, 2021-2035
      • 8.2.1. Biologics
        • 8.2.1.1. Monoclonal Antibodies
        • 8.2.1.2. Recombinant Proteins
        • 8.2.1.3. Vaccines
        • 8.2.1.4. Biosimilars
        • 8.2.1.5. Others
      • 8.2.2. Small Molecules
        • 8.2.2.1. Kinase Inhibitors
        • 8.2.2.2. Enzyme Inhibitors
        • 8.2.2.3. Targeted Small Molecules
        • 8.2.2.4. Others
      • 8.2.3. Nucleic Acid-Based Therapeutics
        • 8.2.3.1. DNA-Based
        • 8.2.3.2. RNA-Based
      • 8.2.4. Cell-Based Products
      • 8.2.5. Tissue Engineering Products
  • 9. Global Therapeutics & Biotech Niche Areas Market Analysis, by Route of Administration
    • 9.1. Key Segment Analysis
    • 9.2. Therapeutics & Biotech Niche Areas Market Size (Value - US$ Bn), Analysis, and Forecasts, by Route of Administration, 2021-2035
      • 9.2.1. Injectable
        • 9.2.1.1. Intravenous
        • 9.2.1.2. Subcutaneous
        • 9.2.1.3. Intramuscular
        • 9.2.1.4. Intrathecal
        • 9.2.1.5. Others
      • 9.2.2. Oral
      • 9.2.3. Topical
      • 9.2.4. Inhalation
      • 9.2.5. Transdermal
      • 9.2.6. Implantable
  • 10. Global Therapeutics & Biotech Niche Areas Market Analysis, by Development Stage
    • 10.1. Key Segment Analysis
    • 10.2. Therapeutics & Biotech Niche Areas Market Size (Value - US$ Bn), Analysis, and Forecasts, by Development Stage, 2021-2035
      • 10.2.1. Preclinical
      • 10.2.2. Clinical Trials
      • 10.2.3. Approved/Marketed
      • 10.2.4. Post-Marketing Surveillance
  • 11. Global Therapeutics & Biotech Niche Areas Market Analysis, by End-users
    • 11.1. Key Segment Analysis
    • 11.2. Therapeutics & Biotech Niche Areas Market Size (Value - US$ Bn), Analysis, and Forecasts, by End-users, 2021-2035
      • 11.2.1. Healthcare Providers
        • 11.2.1.1. Diagnosis & Treatment
        • 11.2.1.2. Patient Monitoring
        • 11.2.1.3. Precision Medicine
        • 11.2.1.4. Others
      • 11.2.2. Research & Academic Institutions
        • 11.2.2.1. Drug Discovery
        • 11.2.2.2. Translational Research
        • 11.2.2.3. Basic Research
        • 11.2.2.4. Others
      • 11.2.3. Pharmaceutical & Biotech Companies
        • 11.2.3.1. Product Development
        • 11.2.3.2. Manufacturing
        • 11.2.3.3. Commercialization
        • 11.2.3.4. Others
      • 11.2.4. Contract Research Organizations (CROs)
        • 11.2.4.1. Clinical Trials
        • 11.2.4.2. Regulatory Support
        • 11.2.4.3. Others
      • 11.2.5. Contract Manufacturing Organizations (CMOs)
        • 11.2.5.1. Commercial Production
        • 11.2.5.2. Process Development
      • 11.2.6. Diagnostic Laboratories
      • 11.2.7. Government & Regulatory Bodies
      • 11.2.8. Other End-users
  • 12. Global Therapeutics & Biotech Niche Areas Market Analysis and Forecasts, by Region
    • 12.1. Key Findings
    • 12.2. Therapeutics & Biotech Niche Areas Market Size (Value - US$ Bn), Analysis, and Forecasts, by Region, 2021-2035
      • 12.2.1. North America
      • 12.2.2. Europe
      • 12.2.3. Asia Pacific
      • 12.2.4. Middle East
      • 12.2.5. Africa
      • 12.2.6. South America
  • 13. North America Therapeutics & Biotech Niche Areas Market Analysis
    • 13.1. Key Segment Analysis
    • 13.2. Regional Snapshot
    • 13.3. North America Therapeutics & Biotech Niche Areas Market Size Value - US$ Bn), Analysis, and Forecasts, 2021-2035
      • 13.3.1. Therapeutic Area
      • 13.3.2. Technology Platform
      • 13.3.3. Molecule Type
      • 13.3.4. Route of Administration
      • 13.3.5. Development Stage
      • 13.3.6. End-users
      • 13.3.7. Country
        • 13.3.7.1. USA
        • 13.3.7.2. Canada
        • 13.3.7.3. Mexico
    • 13.4. USA Therapeutics & Biotech Niche Areas Market
      • 13.4.1. Country Segmental Analysis
      • 13.4.2. Therapeutic Area
      • 13.4.3. Technology Platform
      • 13.4.4. Molecule Type
      • 13.4.5. Route of Administration
      • 13.4.6. Development Stage
      • 13.4.7. End-users
    • 13.5. Canada Therapeutics & Biotech Niche Areas Market
      • 13.5.1. Country Segmental Analysis
      • 13.5.2. Therapeutic Area
      • 13.5.3. Technology Platform
      • 13.5.4. Molecule Type
      • 13.5.5. Route of Administration
      • 13.5.6. Development Stage
      • 13.5.7. End-users
    • 13.6. Mexico Therapeutics & Biotech Niche Areas Market
      • 13.6.1. Country Segmental Analysis
      • 13.6.2. Therapeutic Area
      • 13.6.3. Technology Platform
      • 13.6.4. Molecule Type
      • 13.6.5. Route of Administration
      • 13.6.6. Development Stage
      • 13.6.7. End-users
  • 14. Europe Therapeutics & Biotech Niche Areas Market Analysis
    • 14.1. Key Segment Analysis
    • 14.2. Regional Snapshot
    • 14.3. Europe Therapeutics & Biotech Niche Areas Market Size (Value - US$ Bn), Analysis, and Forecasts, 2021-2035
      • 14.3.1. Therapeutic Area
      • 14.3.2. Technology Platform
      • 14.3.3. Molecule Type
      • 14.3.4. Route of Administration
      • 14.3.5. Development Stage
      • 14.3.6. End-users
      • 14.3.7. Country
        • 14.3.7.1. Germany
        • 14.3.7.2. United Kingdom
        • 14.3.7.3. France
        • 14.3.7.4. Italy
        • 14.3.7.5. Spain
        • 14.3.7.6. Netherlands
        • 14.3.7.7. Nordic Countries
        • 14.3.7.8. Poland
        • 14.3.7.9. Russia & CIS
        • 14.3.7.10. Rest of Europe
    • 14.4. Germany Therapeutics & Biotech Niche Areas Market
      • 14.4.1. Country Segmental Analysis
      • 14.4.2. Therapeutic Area
      • 14.4.3. Technology Platform
      • 14.4.4. Molecule Type
      • 14.4.5. Route of Administration
      • 14.4.6. Development Stage
      • 14.4.7. End-users
    • 14.5. United Kingdom Therapeutics & Biotech Niche Areas Market
      • 14.5.1. Country Segmental Analysis
      • 14.5.2. Therapeutic Area
      • 14.5.3. Technology Platform
      • 14.5.4. Molecule Type
      • 14.5.5. Route of Administration
      • 14.5.6. Development Stage
      • 14.5.7. End-users
    • 14.6. France Therapeutics & Biotech Niche Areas Market
      • 14.6.1. Country Segmental Analysis
      • 14.6.2. Therapeutic Area
      • 14.6.3. Technology Platform
      • 14.6.4. Molecule Type
      • 14.6.5. Route of Administration
      • 14.6.6. Development Stage
      • 14.6.7. End-users
    • 14.7. Italy Therapeutics & Biotech Niche Areas Market
      • 14.7.1. Country Segmental Analysis
      • 14.7.2. Therapeutic Area
      • 14.7.3. Technology Platform
      • 14.7.4. Molecule Type
      • 14.7.5. Route of Administration
      • 14.7.6. Development Stage
      • 14.7.7. End-users
    • 14.8. Spain Therapeutics & Biotech Niche Areas Market
      • 14.8.1. Country Segmental Analysis
      • 14.8.2. Therapeutic Area
      • 14.8.3. Technology Platform
      • 14.8.4. Molecule Type
      • 14.8.5. Route of Administration
      • 14.8.6. Development Stage
      • 14.8.7. End-users
    • 14.9. Netherlands Therapeutics & Biotech Niche Areas Market
      • 14.9.1. Country Segmental Analysis
      • 14.9.2. Therapeutic Area
      • 14.9.3. Technology Platform
      • 14.9.4. Molecule Type
      • 14.9.5. Route of Administration
      • 14.9.6. Development Stage
      • 14.9.7. End-users
    • 14.10. Nordic Countries Therapeutics & Biotech Niche Areas Market
      • 14.10.1. Country Segmental Analysis
      • 14.10.2. Therapeutic Area
      • 14.10.3. Technology Platform
      • 14.10.4. Molecule Type
      • 14.10.5. Route of Administration
      • 14.10.6. Development Stage
      • 14.10.7. End-users
    • 14.11. Poland Therapeutics & Biotech Niche Areas Market
      • 14.11.1. Country Segmental Analysis
      • 14.11.2. Therapeutic Area
      • 14.11.3. Technology Platform
      • 14.11.4. Molecule Type
      • 14.11.5. Route of Administration
      • 14.11.6. Development Stage
      • 14.11.7. End-users
    • 14.12. Russia & CIS Therapeutics & Biotech Niche Areas Market
      • 14.12.1. Country Segmental Analysis
      • 14.12.2. Therapeutic Area
      • 14.12.3. Technology Platform
      • 14.12.4. Molecule Type
      • 14.12.5. Route of Administration
      • 14.12.6. Development Stage
      • 14.12.7. End-users
    • 14.13. Rest of Europe Therapeutics & Biotech Niche Areas Market
      • 14.13.1. Country Segmental Analysis
      • 14.13.2. Therapeutic Area
      • 14.13.3. Technology Platform
      • 14.13.4. Molecule Type
      • 14.13.5. Route of Administration
      • 14.13.6. Development Stage
      • 14.13.7. End-users
  • 15. Asia Pacific Therapeutics & Biotech Niche Areas Market Analysis
    • 15.1. Key Segment Analysis
    • 15.2. Regional Snapshot
    • 15.3. East Asia Therapeutics & Biotech Niche Areas Market Size (Value - US$ Bn), Analysis, and Forecasts, 2021-2035
      • 15.3.1. Therapeutic Area
      • 15.3.2. Technology Platform
      • 15.3.3. Molecule Type
      • 15.3.4. Route of Administration
      • 15.3.5. Development Stage
      • 15.3.6. End-users
      • 15.3.7. Country
        • 15.3.7.1. China
        • 15.3.7.2. India
        • 15.3.7.3. Japan
        • 15.3.7.4. South Korea
        • 15.3.7.5. Australia and New Zealand
        • 15.3.7.6. Indonesia
        • 15.3.7.7. Malaysia
        • 15.3.7.8. Thailand
        • 15.3.7.9. Vietnam
        • 15.3.7.10. Rest of Asia Pacific
    • 15.4. China Therapeutics & Biotech Niche Areas Market
      • 15.4.1. Country Segmental Analysis
      • 15.4.2. Therapeutic Area
      • 15.4.3. Technology Platform
      • 15.4.4. Molecule Type
      • 15.4.5. Route of Administration
      • 15.4.6. Development Stage
      • 15.4.7. End-users
    • 15.5. India Therapeutics & Biotech Niche Areas Market
      • 15.5.1. Country Segmental Analysis
      • 15.5.2. Therapeutic Area
      • 15.5.3. Technology Platform
      • 15.5.4. Molecule Type
      • 15.5.5. Route of Administration
      • 15.5.6. Development Stage
      • 15.5.7. End-users
    • 15.6. Japan Therapeutics & Biotech Niche Areas Market
      • 15.6.1. Country Segmental Analysis
      • 15.6.2. Therapeutic Area
      • 15.6.3. Technology Platform
      • 15.6.4. Molecule Type
      • 15.6.5. Route of Administration
      • 15.6.6. Development Stage
      • 15.6.7. End-users
    • 15.7. South Korea Therapeutics & Biotech Niche Areas Market
      • 15.7.1. Country Segmental Analysis
      • 15.7.2. Therapeutic Area
      • 15.7.3. Technology Platform
      • 15.7.4. Molecule Type
      • 15.7.5. Route of Administration
      • 15.7.6. Development Stage
      • 15.7.7. End-users
    • 15.8. Australia and New Zealand Therapeutics & Biotech Niche Areas Market
      • 15.8.1. Country Segmental Analysis
      • 15.8.2. Therapeutic Area
      • 15.8.3. Technology Platform
      • 15.8.4. Molecule Type
      • 15.8.5. Route of Administration
      • 15.8.6. Development Stage
      • 15.8.7. End-users
    • 15.9. Indonesia Therapeutics & Biotech Niche Areas Market
      • 15.9.1. Country Segmental Analysis
      • 15.9.2. Therapeutic Area
      • 15.9.3. Technology Platform
      • 15.9.4. Molecule Type
      • 15.9.5. Route of Administration
      • 15.9.6. Development Stage
      • 15.9.7. End-users
    • 15.10. Malaysia Therapeutics & Biotech Niche Areas Market
      • 15.10.1. Country Segmental Analysis
      • 15.10.2. Therapeutic Area
      • 15.10.3. Technology Platform
      • 15.10.4. Molecule Type
      • 15.10.5. Route of Administration
      • 15.10.6. Development Stage
      • 15.10.7. End-users
    • 15.11. Thailand Therapeutics & Biotech Niche Areas Market
      • 15.11.1. Country Segmental Analysis
      • 15.11.2. Therapeutic Area
      • 15.11.3. Technology Platform
      • 15.11.4. Molecule Type
      • 15.11.5. Route of Administration
      • 15.11.6. Development Stage
      • 15.11.7. End-users
    • 15.12. Vietnam Therapeutics & Biotech Niche Areas Market
      • 15.12.1. Country Segmental Analysis
      • 15.12.2. Therapeutic Area
      • 15.12.3. Technology Platform
      • 15.12.4. Molecule Type
      • 15.12.5. Route of Administration
      • 15.12.6. Development Stage
      • 15.12.7. End-users
    • 15.13. Rest of Asia Pacific Therapeutics & Biotech Niche Areas Market
      • 15.13.1. Country Segmental Analysis
      • 15.13.2. Therapeutic Area
      • 15.13.3. Technology Platform
      • 15.13.4. Molecule Type
      • 15.13.5. Route of Administration
      • 15.13.6. Development Stage
      • 15.13.7. End-users
  • 16. Middle East Therapeutics & Biotech Niche Areas Market Analysis
    • 16.1. Key Segment Analysis
    • 16.2. Regional Snapshot
    • 16.3. Middle East Therapeutics & Biotech Niche Areas Market Size (Value - US$ Bn), Analysis, and Forecasts, 2021-2035
      • 16.3.1. Therapeutic Area
      • 16.3.2. Technology Platform
      • 16.3.3. Molecule Type
      • 16.3.4. Route of Administration
      • 16.3.5. Development Stage
      • 16.3.6. End-users
      • 16.3.7. Country
        • 16.3.7.1. Turkey
        • 16.3.7.2. UAE
        • 16.3.7.3. Saudi Arabia
        • 16.3.7.4. Israel
        • 16.3.7.5. Rest of Middle East
    • 16.4. Turkey Therapeutics & Biotech Niche Areas Market
      • 16.4.1. Country Segmental Analysis
      • 16.4.2. Therapeutic Area
      • 16.4.3. Technology Platform
      • 16.4.4. Molecule Type
      • 16.4.5. Route of Administration
      • 16.4.6. Development Stage
      • 16.4.7. End-users
    • 16.5. UAE Therapeutics & Biotech Niche Areas Market
      • 16.5.1. Country Segmental Analysis
      • 16.5.2. Therapeutic Area
      • 16.5.3. Technology Platform
      • 16.5.4. Molecule Type
      • 16.5.5. Route of Administration
      • 16.5.6. Development Stage
      • 16.5.7. End-users
    • 16.6. Saudi Arabia Therapeutics & Biotech Niche Areas Market
      • 16.6.1. Country Segmental Analysis
      • 16.6.2. Therapeutic Area
      • 16.6.3. Technology Platform
      • 16.6.4. Molecule Type
      • 16.6.5. Route of Administration
      • 16.6.6. Development Stage
      • 16.6.7. End-users
    • 16.7. Israel Therapeutics & Biotech Niche Areas Market
      • 16.7.1. Country Segmental Analysis
      • 16.7.2. Therapeutic Area
      • 16.7.3. Technology Platform
      • 16.7.4. Molecule Type
      • 16.7.5. Route of Administration
      • 16.7.6. Development Stage
      • 16.7.7. End-users
    • 16.8. Rest of Middle East Therapeutics & Biotech Niche Areas Market
      • 16.8.1. Country Segmental Analysis
      • 16.8.2. Therapeutic Area
      • 16.8.3. Technology Platform
      • 16.8.4. Molecule Type
      • 16.8.5. Route of Administration
      • 16.8.6. Development Stage
      • 16.8.7. End-users
  • 17. Africa Therapeutics & Biotech Niche Areas Market Analysis
    • 17.1. Key Segment Analysis
    • 17.2. Regional Snapshot
    • 17.3. Africa Therapeutics & Biotech Niche Areas Market Size (Value - US$ Bn), Analysis, and Forecasts, 2021-2035
      • 17.3.1. Therapeutic Area
      • 17.3.2. Technology Platform
      • 17.3.3. Molecule Type
      • 17.3.4. Route of Administration
      • 17.3.5. Development Stage
      • 17.3.6. End-users
      • 17.3.7. Country
        • 17.3.7.1. South Africa
        • 17.3.7.2. Egypt
        • 17.3.7.3. Nigeria
        • 17.3.7.4. Algeria
        • 17.3.7.5. Rest of Africa
    • 17.4. South Africa Therapeutics & Biotech Niche Areas Market
      • 17.4.1. Country Segmental Analysis
      • 17.4.2. Therapeutic Area
      • 17.4.3. Technology Platform
      • 17.4.4. Molecule Type
      • 17.4.5. Route of Administration
      • 17.4.6. Development Stage
      • 17.4.7. End-users
    • 17.5. Egypt Therapeutics & Biotech Niche Areas Market
      • 17.5.1. Country Segmental Analysis
      • 17.5.2. Therapeutic Area
      • 17.5.3. Technology Platform
      • 17.5.4. Molecule Type
      • 17.5.5. Route of Administration
      • 17.5.6. Development Stage
      • 17.5.7. End-users
    • 17.6. Nigeria Therapeutics & Biotech Niche Areas Market
      • 17.6.1. Country Segmental Analysis
      • 17.6.2. Therapeutic Area
      • 17.6.3. Technology Platform
      • 17.6.4. Molecule Type
      • 17.6.5. Route of Administration
      • 17.6.6. Development Stage
      • 17.6.7. End-users
    • 17.7. Algeria Therapeutics & Biotech Niche Areas Market
      • 17.7.1. Country Segmental Analysis
      • 17.7.2. Therapeutic Area
      • 17.7.3. Technology Platform
      • 17.7.4. Molecule Type
      • 17.7.5. Route of Administration
      • 17.7.6. Development Stage
      • 17.7.7. End-users
    • 17.8. Rest of Africa Therapeutics & Biotech Niche Areas Market
      • 17.8.1. Country Segmental Analysis
      • 17.8.2. Therapeutic Area
      • 17.8.3. Technology Platform
      • 17.8.4. Molecule Type
      • 17.8.5. Route of Administration
      • 17.8.6. Development Stage
      • 17.8.7. End-users
  • 18. South America Therapeutics & Biotech Niche Areas Market Analysis
    • 18.1. Key Segment Analysis
    • 18.2. Regional Snapshot
    • 18.3. Central and South Africa Therapeutics & Biotech Niche Areas Market Size (Value - US$ Bn), Analysis, and Forecasts, 2021-2035
      • 18.3.1. Therapeutic Area
      • 18.3.2. Technology Platform
      • 18.3.3. Molecule Type
      • 18.3.4. Route of Administration
      • 18.3.5. Development Stage
      • 18.3.6. End-users
      • 18.3.7. Country
        • 18.3.7.1. Brazil
        • 18.3.7.2. Argentina
        • 18.3.7.3. Rest of South America
    • 18.4. Brazil Therapeutics & Biotech Niche Areas Market
      • 18.4.1. Country Segmental Analysis
      • 18.4.2. Therapeutic Area
      • 18.4.3. Technology Platform
      • 18.4.4. Molecule Type
      • 18.4.5. Route of Administration
      • 18.4.6. Development Stage
      • 18.4.7. End-users
    • 18.5. Argentina Therapeutics & Biotech Niche Areas Market
      • 18.5.1. Country Segmental Analysis
      • 18.5.2. Therapeutic Area
      • 18.5.3. Technology Platform
      • 18.5.4. Molecule Type
      • 18.5.5. Route of Administration
      • 18.5.6. Development Stage
      • 18.5.7. End-users
    • 18.6. Rest of South America Therapeutics & Biotech Niche Areas Market
      • 18.6.1. Country Segmental Analysis
      • 18.6.2. Therapeutic Area
      • 18.6.3. Technology Platform
      • 18.6.4. Molecule Type
      • 18.6.5. Route of Administration
      • 18.6.6. Development Stage
      • 18.6.7. End-users
  • 19. Key Players/ Company Profile
    • 19.1. 10x Genomics, Inc.
      • 19.1.1. Company Details/ Overview
      • 19.1.2. Company Financials
      • 19.1.3. Key Customers and Competitors
      • 19.1.4. Business/ Industry Portfolio
      • 19.1.5. Product Portfolio/ Specification Details
      • 19.1.6. Pricing Data
      • 19.1.7. Strategic Overview
      • 19.1.8. Recent Developments
    • 19.2. AbbVie Inc.
    • 19.3. Alexion Pharmaceuticals (AstraZeneca)
    • 19.4. Alnylam Pharmaceuticals, Inc.
    • 19.5. Amgen Inc.
    • 19.6. Biogen Inc.
    • 19.7. BioMarin Pharmaceutical Inc.
    • 19.8. BioNTech SE
    • 19.9. bluebird bio, Inc.
    • 19.10. Bristol-Myers Squibb Company
    • 19.11. CRISPR Therapeutics AG
    • 19.12. Editas Medicine, Inc.
    • 19.13. Genentech (Roche Group)
    • 19.14. Gilead Sciences, Inc.
    • 19.15. Illumina, Inc.
    • 19.16. Intellia Therapeutics, Inc.
    • 19.17. Ionis Pharmaceuticals, Inc.
    • 19.18. Moderna, Inc.
    • 19.19. Novartis AG
    • 19.20. Regeneron Pharmaceuticals, Inc.
    • 19.21. Roche Holding AG
    • 19.22. Sarepta Therapeutics, Inc.
    • 19.23. Vertex Pharmaceuticals Incorporated
    • 19.24. Other Key Players

Note* - This is just tentative list of players. While providing the report, we will cover more number of players based on their revenue and share for each geography

Get PDF
PRICING DETAILS
USD 4150
USD 5950
USD 7750
Related Report  
YOU MAY ALSO LIKE
Algae Protein Market by Source Type, Form, Protein Content, Production Method, Nature, Extraction Technology, Grade, End-Use Industry, and Geography
Alternative Protein Market by Source/Type, Form, Product Type, Processing Technology, Distribution Channel, Protein Content, End-users, and Geography
Astaxanthin Market by Source/Origin, Form, Grade/Purity Level, Concentration Level, Production Technology, End-users, Distribution Channel, Packaging Type, and Geography
Discount On Multiple Reports

Where did We Help Most?

Custom Market Research Services

We will customise the research for you, in case the report listed above does not meet your requirements.

Get 10% Free Customisation